Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more

Recent & Breaking News (NDAQ:EQ)

Equillium to Present at Two Upcoming Investor Conferences

Business Wire August 31, 2022

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

Business Wire August 15, 2022

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

Business Wire July 28, 2022

Equillium to Present at Two Upcoming Investor Conferences

Business Wire May 17, 2022

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

Business Wire May 12, 2022

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

Business Wire May 12, 2022

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

Business Wire May 9, 2022

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

Business Wire April 25, 2022

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

Business Wire April 4, 2022

Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

Business Wire March 23, 2022

Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Business Wire March 23, 2022

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Business Wire March 4, 2022

Equillium Announces Appointment of Barbara Troupin to Board of Directors

Business Wire March 1, 2022

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

Business Wire February 16, 2022

Equillium Provides Timing Update on Conference Presentations

Business Wire February 15, 2022

Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

Business Wire February 9, 2022

Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR

Business Wire January 10, 2022

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

Business Wire January 5, 2022

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

Business Wire January 4, 2022

Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

Business Wire January 4, 2022